Lenvatinib/lenvatinib medical insurance reimbursement price and description

Lenvatinib/Lenvatinib (Lenvatinib), as a domestically marketed anti-cancer targeted drug, has been included in the national medical insurance catalog, providing certain financial support to eligible patients. The specific reimbursement prices vary according to medical insurance policies, regional differences and hospital procurement conditions, but in general, medical insurance coverage can significantly reduce patients' out-of-pocket burden. Usually, after the patient is diagnosed by a doctor and meets the indications, the drug cost can be reimbursed according to the prescribed proportion through a prescription issued by the hospital and reviewed by the medical insurance.

In terms of indications, lenvatinib is mainly used to treat radioiodine-refractory differentiated thyroid cancer, unresectable hepatocellular carcinoma, renal cell carcinoma, and advanced endometrial cancer. Medical insurance reimbursement usually requires patients to have a clear pathological diagnosis and to fall within the scope of drug approval indications. In some areas, the medical insurance reimbursement ratio will vary according to the medical insurance level, outpatient or inpatient classification. Generally, the reimbursement ratio can reach about 50% to 70%, which can significantly reduce the financial burden for patients with heavy financial burdens.

It is worth noting that the medical insurance reimbursement policy not only covers the drug itself, but may also involve related diagnosis and treatment costs during drug use, such as hematology monitoring, liver function testing, and imaging examinations. During the period of treatment with lenvatinib, patients need to follow the doctor's guidance for regular follow-up to ensure the efficacy and safety of the drug and meet the medical insurance reimbursement requirements. In addition, medical insurance policies may differ in different regions. Patients should consult the medical insurance department of their hospital to obtain the latest reimbursement information before purchasing drugs.

In short, after lenvatinib is included in medical insurance, it provides a more reliable treatment option for patients with advanced cancer. At the same time, it relieves some economic pressure through the medical insurance reimbursement mechanism, allowing patients to continue and standardize the use of targeted therapy drugs under the guidance of clinicians, improving treatment compliance and quality of life.

Reference materials:https://www.lenvima.com/